Cancer associated with asbestos
POPULARITY
34 episodes with Mesothelioma
7 episodes with Mesothelioma
3 episodes with Mesothelioma
2 episodes with Mesothelioma
3 episodes with Mesothelioma
5 episodes with Mesothelioma
3 episodes with Mesothelioma
2 episodes with Mesothelioma
2 episodes with Mesothelioma
Quincy Jones is hilarious comedian from Seattle, WA, who was diagnosed with Mesothelioma last July, and given only a year to live. His inspiring fight will not only move you, but make you laugh, and sharpen your appreciation of life. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sydney psychiatrist Jim Holmes wrote a diary covering his early bouts of recurrent pneumonia, leading to his eventual diagnosis of mesothelioma and developing illness.
Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.
Dublin's Trinity College researchers have announced a potential breakthrough in relation to a cancer that kills up to 50 people a year. The offending condition is called Mesothelioma the team lead is Prof Patrick Forde and he joined us from the World Conference on Lung Cancer in Barcelona.
On this episode of Cancer Registry World, we shine a spotlight on The Mesothelioma Center in Orlando, Florida—a trusted resource dedicated to supporting patients and families navigating a mesothelioma diagnosis. Joining us are Jose Ortiz, Medical Outreach Liaison, and Karen Selby, Registered Nurse and Board-Certified Patient Advocate, who share how patient education, advocacy, and the power of cancer registry data come together to improve lives.
In this episode, we review the high-yield topic Mesothelioma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Clarence Ford spoke to Professor David Kinley on his new book: In a Rain of Dust: Death, Deceit and the effects of South Africa’s asbestos mining legacy. Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.
where the skies are so blue Checkout MyBookie for the best and most awesome LIVE CASINO https://www.mybookie.ag/Support the show
Sandra M. Oliver-McNeil, DNP, ACNP-BC, FACC, JACC: Case Reports Associate Editor, is joined by author Victor A. Ferrari, MD, FACC discussing this study from Ravindra et al presented at ACC.25 and published in JACC: Case Reports. This clinical vignette highlights the case of a 62-year-old male who presented with worsening dyspnea and was ultimately found to have constrictive pericarditis secondary to primary pericardial mesothelioma. The use of multimodality imaging can facilitate early diagnosis of this rare condition, helping to initiate treatment options for an otherwise high-mortality disease.
Send us a text
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. Guests Melina Marmarelis, MD MSCE Assistant Professor Medical Director, UPenn Mesothelioma University of Pennsylvania Jia Luo, MD Medical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer Institute Faculty, Brigham and Women's Hospital and Harvard Medical School
EP263*IF YOU ARE LISTENING TO THIS AUDIO PORTION ON YOUTUBE, SWITCH OVER TO THE VIDEOJohn Vasos first two appearances below:➡️ EP116: https://youtu.be/YPji5Yu8UCQ?si=ni0Ny4jMFoG-q846➡️ EP219: https://youtu.be/inBQ0Z_Xjy4?si=6HgN2Dw2l1uy8TE5This John Vasos conversation was recorded in April of 2024. Guest Jake Cole was added for this episode to revisit his role on bringing John Vasos essentially to Hard Parking. On February 11, 2025, John Vasos lost his battle with Mesothelioma at the age of 68 after losing his long battle with Mesothelioma. This is his 3rd time on Hard Parking but this episode was never meant to be a podcast, but instead a recorded collection of valuable Acura NSX information from the heart and mind of one of America's Mount Rushmore of Acura NSX minds. Many thanks to content contributors of this video:Mary E BushPeter CunninghamJake ColeMatt ColeLeon SchmidtBryan HunterDr. Ajay SharmakeN SaXChris WillsonEmma MikolicJohn is survived by his son, daughter, and brother.Contact Hard Parking with Jhae Pfenning:email: HardParkingPodcast@gmail.comWebsite: www.Hardparkingpod.comPatreon: www.patreon.com/hardparkingpodcast/Instagram: instagram.com/hardparkingpod/YouTube: https://youtube.com/@HardParking
Send us a text
Send us a text
Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics including surgery, immunotherapy, chemotherapy, pathology, and germline testing. Dr. Kindler describes the impact of this guideline and the need for ongoing research in the field. Read the full guideline update, “Treatment of Pleural Mesothelioma: ASCO Guideline Update” at www.asco.org/thoracic-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02425 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Hedy Kindler from the University of Chicago, lead author on “Treatment of Pleural Mesothelioma: ASCO Guideline Update.” Thank you for being here today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines in ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Kindler, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to jump into the content of this podcast episode, first, Dr. Kindler, can you provide an overview of the purpose and scope of this guideline update on pleural mesothelioma? Dr. Hedy Kindler: The initial ASCO practice guideline on mesothelioma, which we published in 2018, was quite comprehensive, but since that time incredible progress has been made which has truly transformed the management of this disease. So we felt it was really important to update the guideline now, focusing on four key areas: the role of surgery, new systemic treatments, pathologic insights, and germline testing. Brittany Harvey: Great. Thank you for highlighting those key areas of the guideline. And so I'd like to next review the key updated recommendations for our listeners. So starting with what are the new updates for surgery? Dr. Hedy Kindler: So surgery has always been controversial in meso, with significant geographic variation in its use. Now, it's even more controversial. Recent randomized data from the MARS 2 trial, placed in the context of other data we also reviewed in this update, suggest that surgical cytoreduction should not be routinely offered to all patients based solely on anatomic resectability. Surgery should only be offered to highly selected patients with favorable prognostic characteristics. This includes comprehensively staged patients with early-stage epithelioid tumors. Patients should preferably be treated at centers of excellence which have documented low morbidity and mortality, and this should also be done in the context of multimodality therapy and preferably within clinical trials. Brittany Harvey: Understood. I appreciate you reviewing those recommendations for who surgery should be offered to. So following those, what are the main recommendations for immunotherapy for treating pleural mesothelioma? Dr. Hedy Kindler: So for a disease in which for 16 years there was only one FDA-approved regimen, pemetrexed and platinum, the pace of recent changes in systemic therapy has been a welcome change with the FDA approval of doublet immunotherapy in October of 2020 and the approval of chemo immunotherapy just a few months ago in September of 2024. Now that we have choices, we've tried to help clinicians determine the optimal treatment regimen for the individual patient. Doublet immunotherapy with ipilimumab and nivolumab should be offered as a first-line systemic option to any mesothelioma patient. For patients with non-epithelioid histology, doublet immunotherapy is hands down the recommended regimen based on the dramatic improvement in survival from 8.8 to 18.1 months for immunotherapy compared with chemo. For patients with previously untreated epithelioid mesothelioma, either ipilimumab-nivolumab immunotherapy or platinum-pemetrexed chemotherapy are reasonable options. Therapy can be individualized based on the patient's comorbidities, acceptance of differing toxicities. and treatment goals. Chemoimmunotherapy with pembrolizumab, pemetrexed, and carboplatin is a newer treatment option for patients with newly diagnosed pleural mesothelioma. This regimen is noteworthy for its very high objective response rate of 62%. Brittany Harvey: It's great to have those new options to improve outcomes for patients. Beyond the chemoimmunotherapy recommendation that you just described, what are the highlights for chemotherapy recommendations? Dr. Hedy Kindler: So pemetrexed platinum-based chemotherapy with or without bevacizumab still plays a role in this disease and should be offered as a first-line treatment option in patients with epithelioid histology. This regimen is not recommended in patients with non-epithelioid disease unless they have medical contraindications to immunotherapy. Pemetrexed maintenance chemotherapy following pemetrexed-platinum chemotherapy is not recommended. Brittany Harvey: Thank you for reviewing those recommendations as well. So then next, what are the important changes regarding pathology? Dr. Hedy Kindler: Well, one fun fact is that we've changed the name of the disease. It's no longer malignant mesothelioma. Now it's just mesothelioma. Since the non-malignant mesothelial entities have been renamed, all mesos are now considered malignant, so there's no need to use the prefix malignant in the disease name. Mesothelioma should be reported as epithelioid, sarcomatoid, or biphasic because these subtypes have a clear prognostic and predictive value. Knowing the subtype helps us decide on whether chemotherapy or immunotherapy is the optimal treatment for a patient, so it must be reported. Additionally, within the epithelioid subtype, histologic features, including nuclear grade, some cytologic features, and architectural patterns should be reported by pathology because they have prognostic significance. Pathologists have recently identified a premalignant entity, mesothelioma in situ, which can be found in patients with long standing pleural effusions and should be considered in the differential diagnosis. In the appropriate clinical setting, additional testing, including BAP1 and MTAP IHC should be performed. Brittany Harvey: Definitely. These pathologic recommendations are important for treatment selection. So in that same vein, in the final section of the recommendations, what are the updated recommendations from the panel regarding germline testing? Dr. Hedy Kindler: This is one of our most important recommendations, that universal germline testing should be offered to all mesothelioma patients. The proportion of patients with mesothelioma who have pathogenic or likely pathogenic germline variants is similar to other diseases in which universal germline genetic testing and counseling are now the standard of care. This is most commonly observed in the tumor suppressor gene BAP1 and this not only affects cancer risk in patients and their family members, but also has key prognostic significance. For example, pleural mesothelioma patients with BAP1 germline mutations who receive platinum-based chemotherapy live significantly longer, 7.9 years compared to 2.4 years for those without these mutations. Thus, we recommend that all patients with mesothelioma should be offered universal germline genetic counseling and/or germline testing. Brittany Harvey: So there were a large amount of new and updated recommendations in this update. So in your view Dr. Kindler, what is the both importance of this update and how will it impact both clinicians and patients with pleural mesothelioma? Dr. Hedy Kindler: Even as we were researching and writing this update, new data kept emerging which we needed to include. So it's clearly a time of great progress in the management of this disease. We've comprehensively reviewed and analyzed the extensive emerging data and provided clinicians with a roadmap for how to incorporate these new advances into their management of this disease. Brittany Harvey: Absolutely, that is key for optimal patient care. So you've just mentioned emerging data and rapid evidence generation, so what future research developments are being monitored for changes in the treatment of pleural mesothelioma? Dr. Hedy Kindler: Despite these recent advances in disease management, mesothelioma continues to be a lethal cancer, and there's clearly a need to develop better treatments. This includes ongoing studies of novel immunotherapeutic agents such as bispecific antibodies, cell therapy using chimeric antigen receptors targeting mesothelioma tumor antigens, and precision medicine approaches to target tumor suppressor genes. Finally, strategies for early cancer detection and prevention are vital for individuals predisposed to develop mesothelioma due to BAP1 and other germline mutations, as well as for those who are occupationally or environmentally exposed to asbestos. Brittany Harvey: Absolutely. We'll look forward to these new updates to continue development in the field. So thank you so much for this mountain of work to update this guideline, and thank you for your time today, Dr. Kindler. Dr. Hedy Kindler: Thank you so much. It's been a pleasure. Thank you for asking me to do this. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline update, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Greetings, dear listener, and welcome back to "Jump on the Bat-Wagon" with James and Brian, where we watch through the entire DC Animated Universe from start to finish in the controversial airdate order, to experience these shows the way human beings experienced them in the far-gone days of the 1990s. The twist? Brian has never seen any of the DCAU. Will he become a super-fan like James or regret his decision? This week's episode: "Little Big Head Man" "Superman: The Animated Series" Original airdate: 11/21/1998 Mr. Mxyptlk gets into trouble with the rulers of his planet when he enlists Bizarro's help to create havoc on Earth. Timecodes: 0:00 - Intro 17:17 - Review and Ratings 59:25 - Yoppie Mail 1:23:05 - Outro Next episode: Bonus: The Yopisode Guide (Most of STAS and TNBA) DCAU Airdate Viewing Order: https://bit.ly/watchdcau Send us an email! batwagonpod @gmail Buy us a coffee! https://www.buymeacoffee.com/yoppie Buy a Yoppie Dude T-Shirt! https://watchtowerdatabase.com/shop New episodes debut Fridays on the Podtower YouTube channel and your favorite podcast feed! https://www.youtube.com/thepodtower Subscribe to the Watchtower Database for more DCAU videos! https://www.youtube.com/watchtowerdatabase Hang out with us on Discord! https://discord.com/invite/RWZ7TaxAar
Nicholas Vogelzang of Vogelzang Law joins Jon Hansen on Let's Get Legal to discuss why Illinois is important to asbestos litigation and why there are so many cases tried here. For more information, call (312) 466-1669.
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.
The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis
In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute's New Drug Development Program and CCTG Investigational New Drug Committee Chair
Over the course of the last couple of years, I, like you, have seen countless television commercials for law firms inviting viewers to engage in lawsuits for a variety of causes, many times because of exposure to contaminants at Camp LeJeune, or for illnesses like Mesothelioma. I've often times turned to my wife to tell her that we are not far from seeing the same kinds of ads pop up for those who were encouraged and perhaps forced into gender transitioning steps by parents, medical doctors, educators, and others. The reality is that several suits are now in progress, and there are law firms working to announce their willingness to represent detransitioners who want to sue those who lied about the dangers of these medical interventions. Parents, this reminds us of our need to not only advocate for our kids with sensibility, but to do so from a biblical perspective. At creation, God made two genders, and he has created all people to live into the gender that was given at conception.
Michelle T. Pawlowski, Litigation Associate Attorney at Vogelzang Law, joins Jon Hansen on Let’s Get Legal! Michelle and Jon talk about the development of Mesothelioma, the investigation of cases, and what clients should look for in an attorney. How Michael Madigan’s case will be affected by the overturning of the bribery conviction of former Indiana […]
BUFFALO, NY- July 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.” Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and affected patients have low survival rates. In this new retrospective study, researchers Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, and Koichiro Yamakado from Hyogo Medical University and Kindai University Faculty of Medicine examined the effectiveness of fluorodeoxyglucose positron emission tomography (FDG-PET) criteria, i.e., immunotherapy-modified PET response criteria in solid tumors (imPERCIST), with morphological computed tomography (CT) criteria, i.e., modified response evaluation criteria in solid tumors (mRECIST), to evaluate patients with unresectable MPM undergoing nivolumab plus ipilimumab combination therapy as first-line treatment regarding response and prognosis prediction. “Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F] (FDG-PET/CT), and modified RECIST (mRECIST), shown by CT, were compared for response evaluation and prognosis prediction.” Twenty-six patients (23 males, 3 females; median 73.5 years) with histologically proven MPM and no curative surgery received nivolumab plus ipilimumab combination therapy. FDG-PET/CT and diagnostic CT scanning at the baseline, and after 2–4 cycles (2 in three, 3 in 17, 4 in six patients) were performed. Therapeutic response findings evaluated using imPERCIST and mRECIST were compared. PFS and OS analyses were done using log-rank and Cox methods. Results: imPERCIST indicated nine progressive metabolic disease (PMD), eight stable metabolic disease (SMD), four partial metabolic response (PMR), and five complete metabolic response (CMR) cases. mRECIST showed nine with progressive disease (PD), nine stable disease (SD), seven partial response (PR), and one complete response (CR). Although high concordance was noted (κ = 0.827), imPERCIST correctly judged a greater percentage with CMR (15.4%). Following a median 10.0 months, 15 patients showed progression and eight died from MPM. With both, progression-free survival (PFS) and overall survival (OS) were significantly longer in patients without progression (CMR/PMR/SMD, CR/PR/SD, respectively) as compared to PMD/PD patients (imPERCIST p < 0.0001 and p = 0.015, respectively; mRECIST p < 0.0001 and p = 0.015, respectively). “For unresectable MPM patient examinations, FDG-PET and CT provide accurate findings for evaluating tumor response and also prognosis prediction following first-line nivolumab plus ipilimumab immunotherapy (approximately three cycles).” DOI - https://doi.org/10.18632/oncotarget.28594 Correspondence to - Kazuhiro Kitajima - kazu10041976@yahoo.co.jp Video short - https://www.youtube.com/watch?v=7ZRTRwig60Y About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
Mesothelioma, lung cancer from asbestos exposure, asbestosis, and other personal injury cases, are the cases that Vogelzang Law is helping people with. Nicholas Vogelzang of Vogelzang Law joins Jon Hansen on Let’s Get Legal to discuss how he started the law firm and the types of cases he’s seen. Mesothelioma is a cancer of the […]
ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.Links to studies discussed in this episode (subscription may be required):BEAT-meso: Link Checkmate 816 4 year update: LinkMIST5: LinkctDNA-Lung-DETECT: Link BEAT-SC: Link For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
Professor Eric Lim discusses the outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this episode our team dives into the diagnosis, workup and management of malignant pleural mesothelioma. Listen as we debate the pros and cons of surgical management of this disease with extrapleural pneumonectomy versus pleural decortication and discuss the nuances of choosing the right approach for the right patient. Learning Objectives - Describe the workup and staging of a patient with malignant pleural mesothelioma - List the subtypes of malignant pleural mesothelioma, characteristics of resectable disease, and patient factors which impact surgical candidacy - Describe the approach to an extrapleural pneumonectomy and pleural decortication - Analyze which surgical approach is best for various subsets of patients - Describe the adjuvant treatment for malignant pleural mesothelioma Hosts Kelly Daus MD, Adam Bograd MD, Peter White MD, Brian Louie MD Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out more recent episodes: https://app.behindtheknife.org/listen
On this episode of Speeding Bullitt: The Life and Films of Steve McQueen, I'm joined by Marshall Terrill, writer and Steve McQueen expert. Together, we explore McQueen's relationship with his third wife, Barbara Minty, his struggle with Mesothelioma, and his passing on November 7, 1980.
In the first episode of Glauc Talk, Will and Kristin sit down to talk about the Change Healthcare cyber attack and how it compared to the Anthem cyber attack of 2015, they have a little couple therapy moment where they tell each other something they are wrong about, and Will tries to remember a disease associated with the Mesothelium. — We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! – http://www.patreon.com/glaucomflecken -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit http://www.EyelidCheck.com for more information. This episode is brought to you by pRxcision. To see a demo, Go to http://www.prxcision.com/kkh. Today's episode is brought to you by the Nuance Dragon Ambient Experience (DAX). It's like having a virtual Jonathan in your pocket. If you would like to learn more about DAX Copilot check out http://nuance.com/discoverDAX and ask your provider for the DAX Copilot experience. Produced by Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices
In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothelioma, the emerging roles of immunotherapy and biomarker testing, and the importance of ensuring access to care for patients with this rare disease.
MesoTV Podcast: Conversations Impacting the Mesothelioma Community
Melina Marmarelis, MD, Thoracic Medical Oncologist, UPenn joins us for an interview about precision medicine. She discusses biomarker information, such as histology (currently most valuable), but also molecular testing such as NF2, MTAP, CDKN2A mutations that can be used when determining precision medicine treatments. Other topics discussed are BAP1 mutations, PDL1 expression, mutational burden, and oncolytic viruses. The interview is moderated by Julie White, BSN, OCN, RN who is the patient services director at the Mesothelioma Applied Research Foundation. More information is available at curemeso.org.
This week's episode will be focusing on Malignant Mesothelioma. We will go over the important details on diagnosis, work-up, the different subtypes, and staging as well as treatment options for operable and inoperable disease.
Host Tom Simmons is joined by our guests from the law firm Brown Rudnick LLP, Partner Kyle Johnson and Counsel Anthony J. Boccamazzo, as well as HRP's CEO Dan Titus, to discuss PFAS in the context of class action lawsuits. Perhaps you've been struck, like us, by the similarities between class action lawsuit advertising for PFAS related injuries and asbestos related mesothelioma. It got us interested in the history of similar class action lawsuits and what that could tell us about the future of PFAS litigation.Join us for a great conversation. Listen to learn more and subscribe to The Pulse for all the details. Listen to learn more and subscribe to The Pulse for all the details.
O se tala fiafia le ono maua i se taimi lata mai o se su'ega poo se test e vave iloa ai ma togafitia tagata e a'afia i le mesothelioma, o se kanesa e mafua mai i le manavaina o le pefu o le asbestos.
MesoTV Podcast: Conversations Impacting the Mesothelioma Community
Michael Offin, MD, MSKCC, joins us for an informative session about chemotherapy drugs, their uses, side effects, and supportive medications.
James Hardie Industries' involvement in the asbestos industry significantly shaped its trajectory from the mid-20th century. By the 1930s, the company had begun producing asbestos-containing products, capitalizing on the material's fire-resistant and insulating properties. This move propelled James Hardie into a dominant position within the asbestos industry, with its products widely used in construction throughout Australia and globally. However, by the 1970s, concerns about asbestos-related health risks began to emerge, leading to a shift in public perception and regulatory scrutiny.Join Matthew and Holly as they work their way through the history of the company who has become synonymous with asbestos exposure, their deeds and missteps, court cases and extradition treaties.
James Hardie Industries' involvement in the asbestos industry significantly shaped its trajectory from the mid-20th century. By the 1930s, the company had begun producing asbestos-containing products, capitalizing on the material's fire-resistant and insulating properties. This move propelled James Hardie into a dominant position within the asbestos industry, with its products widely used in construction throughout Australia and globally. However, by the 1970s, concerns about asbestos-related health risks began to emerge, leading to a shift in public perception and regulatory scrutiny.Join Matthew and Holly as they work their way through the history of the company who has become synonymous with asbestos exposure, their deeds and missteps, court cases and extradition treaties.
Baryulgil mine, situated in north-east NSW, gained prominence for asbestos extraction during the mid-20th century. While it initially provided economic opportunities for the Baryulgil Indigenous community through employment, the mine's asbestos production later caused severe injury to said workers. Those workers faced asbestos-related diseases like mesothelioma and asbestosis, diseases that destroy the lung tissue and leave sufferers gasping for air.Over time, heightened awareness of asbestos dangers led to the mine's scrutiny and eventual closure. Join Holly & Matthew as they go through the worker safety debates and the environmental challenges offered by such an event, journeying into the complexities of a community caught between progress and peril.
Over the course of the last couple of years, I, like you, have seen countless television commercials for law firms inviting viewers to engage in lawsuits for a variety of causes, many times because of exposure to contaminants at Camp LeJeune, or for illnesses like Mesothelioma. I've often times turned to my wife to tell her that we are not far from seeing the same kinds of ads pop up for those who were encouraged and perhaps forced into gender transitioning steps by parents, medical doctors, educators, and others. The reality is that several suits are now in progress, and there are law firms working to announce their willingness to represent detransitioners who want to sue those who lied about the dangers of these medical interventions. Parents, this reminds us of our need to not only advocate for our kids with sensibility, but to do so from a biblical perspective. At creation, God made two genders, and he has created all people to live into the gender that was given at conception.
Thank you to our Sponsor: Quip - If you go to getquip.com/trashtuesday right now, you'll get 20% any Electric Toothbrush, Mint & Gum Dispenser, Water Flosser. Quip - the good habits company. FINALLY! Trash Tuesday Merch!! Get it at https://itstrashtuesday.com/ See Esther on tour. Check out dates at estheronice.com See Annie on tour. Check out dates at https://www.annielederman.com/shows More Michael Blaustein: Instagram - https://www.instagram.com/blaucomedy/ Twitter - https://twitter.com/blaucomedy/ https://www.blaucomedy.com/ Stiff Socks Podcast - https://trevorwallacecomedy.com/stiff-socks 00:00 - Blaustein's upset there's not a pedicure 02:01 - Bluastein is here and dressed like a cow 08:03 - Rumors about Blaustein's member 10:30 - Blaustein taught many people how to kiss 13:00 - Korean Spa spy revealed 17:00 - Blaustein's foot criteria 23:45 - How old were you when you realized that you look at feet and get a boner 27:58 - Rating Khalyla's feet 32:10 - Thigh gaps 34:30 - Revisiting the boxer brief debate 40:20 - Stinky feet vs. clean feet 45:40 - Have you ever had really in-love sex 49:40 - Mesothelioma and hyper mobility 53:50 - Four hall passes a year 57:53 - Cuck fantasies 01:02:40 - Thrinder 01:04:30 - A couple's third Subscribe! https://bit.ly/HitOurButtonsOfficial Clips Channel: https://bit.ly/2QDAi8X Trash Tuesday Podcast iTunes Audio Feed: https://bit.ly/TrashTuesdayPodTrash Tuesday Podcast Spotify Audio Feed: https://bit.ly/TTPodAudioTrash Tuesday Instagram: https://www.instagram.com/itstrashtuesday Listen to our other Podcasts: TigerBelly - https://podcasts.apple.com/us/podcast/tigerbelly/id1041201977 Rick and Esther Have a Time - https://podcasts.apple.com/us/podcast/rick-and-esther-have-a-time/id1694264079 AnnieWood - https://podcasts.apple.com/us/podcast/anniewood/id1653515392 Follow Us: Khalyla Kuhn - https://www.instagram.com/khalamityk Annie Lederman - https://www.instagram.com/annielederman Esther Povitsky - https://www.instagram.com/esthermonster Theme Song Written by: Bobby Lee http://instagram.com/bobbyleelive Banana Break Song by: Can Nguyen
Mesothelioma is a particularly challenging cancer to treat and there had been relatively few updates in its management until the recent integration of immunotherapy into treatment guidelines. To discuss current strategies to treat Mesothelioma, Dr. Stephen Liu leads an informed discussion with two international Mesothelioma experts.
A long-awaited antitrust case against Amazon's massive online retail operations is expected to be filed in federal court as soon as Tuesday, according to three people with knowledge of the matter. The Federal Trade Commission has been preparing a complaint since at least the start of this year targeting an array of Amazon's business practices. Also, is SCOTUS going after abortion pills? In a case that takes up the availability of widely used abortion pill mifepristone, justices could decide whether a single court can limit abortion access in states that protect it, as well as roll back Food and Drug Administration drug approvals.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Mat Britton is a well-known physiotherapist and local legend who has been part of the Greater Springfield community for many years. He played an integral part in founding the Springfield Runners Group well over a decade ago and through his passion for sport and running, has been able to treat and get people back doing whatever they love to do. In 2014, Mat founded "Trail to Triumph - Tony's Journey" in memory of his dad Tony, who sadly lost his battle to Mesothelioma in March 2014. In October that year TTT was born with the first 250km ultramarathon from Mackay to Moranbah run completed over 2 1/2 gruelling days. It's been run every October and again this year, runners will attempt to complete the 250km Moranbah to Mackay journey from the October 6th - 8th. The event not only is held in memory of Tony Britton but it works to raise awareness and funds to assist in assessment, treatment and research for Mesothelioma and others lung diseases like Silicosis. You can donate to the cause at the below links. As you'll hear in the conversation, Mat has been overwhelmed and truly grateful for the support he has and continues to receive throughout the year through not only the run but also events such as Annual Golf Day, Trivia Night, Brushes and Bubbles and the Virtual Events run. When you attend a function or if you're fortunate enough attend the run up north, you become part of the TTT family which has grown to large numbers, which can be seen by the record group heading up this year. In the conversation with Mat, Steve talks to him about life, how he became a Physio, his reflections on sport, his time in martial arts and plenty of stories in between. It's his love and passion for TTT that truly is a delight within the discussion and his unwavering focus on helping to make a difference to those suffering and experiencing lung diseases that really shines. Follow Mat Instagram Check out Trail to Triumph Instagram Visit their website Trail To Triumph Donate Here Trail To Triumph Runners Disclaimer: Important Notice The information provided in Share Podcast is for general informational purposes only. We are not experts in the discussed subjects, and our opinions are personal. While we aim for accuracy, we don't guarantee the completeness or reliability of the information. This podcast should not be considered a substitute for professional advice. Always consult qualified experts for specific advice. We are not liable for any decisions made based on the podcast content. The opinions expressed are those of individuals and not representative of any affiliated entities. The content is protected by copyright and unauthorized use is prohibited.
This session will review state of the art therapy for peritoneal mesothelioma. The discussion includes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as well as systemic chemotherapy and immunotherapy. Edward Levine, MD, moderates this podcast and is Professor of Surgery and Chief, Surgical Oncology at Wake Forest University. Trang Nguyen, MD, is an Assistant Professor of Surgery at Indiana University and Sinziana Dumitra, MD, MSc, FRCSC, FSSO, is an Assistant Professor of Surgery at McGill University.
Welcome to episode 184 of the Grow Your Law Firm podcast, hosted by Ken Hardison. In this episode, Ken sits down with Mirena Umizaj from Mirena & Company, to discuss how you can diversify your law firm by growing your firm's inventory. In the past decade, Mirena successfully deployed a billion dollars to law firms nationwide. She has worked on the largest class-action suits and mass tort settlements in the United States, including the BP Oil spill, IVC Filter, Mesothelioma, Transvaginal Mesh, RoundUp, Hernia Mesh, Boy Scouts, Opioids, Human Trafficking, Route 91-Las Vegas Shooting, Military Earplugs, Talcum Powder, and JUUL litigations. Mirena is also a Settlement Planning specialist who goes beyond the standard legal conventions, infusing thoughtful and flexible options to clients who receive a recovery. Whether for the Plaintiff or Firm, she improves their bottom line, helping them achieve financial goals of any size and nature. Best of all, her compassion for the plight of the claimant sets her above the rest as she ascertains their well-being through the entire process of the litigation. Mirena's knack for finance and heart to serve provides firms and plaintiffs with holistic, intuitive, and integrated planning to create cutting-edge portfolios. To bring it all full circle, Mirena supplies firms with comprehensive legal concierge services by giving Plaintiffs and Attorneys smooth procedures, detailed reports, and systems of navigating legal planning and funding complexities. By her awareness of market trends and how it affects all aspects of the law she offers a strategic edge in civil justice. She has the wherewithal, drive, discipline, and passion for directing and participating in cases that change our world. Mirena's career began in UNICEF, working as a translator for American troops who assisted Kosovos genocide victims. She subsequently found her way into the US Department of Justice & Immigration, paving the way for her outstanding reputation today. At the young age of 17, Mirena immigrated to the United States from Albania. She earned her degree with honors in International Relations and Communications, graduating from Rollins College in Winter Park, Florida. She fluently speaks three languages, frequently traveling between the US and Europe. What you'll learn about in this episode: How Mirena got started in the legal business Learn how to grow your inventory Why you should think of your law firm as a business You should stop resisting CFO's How Mirena & Co help law firm owners Resources: www.mirenaandco.com https://www.facebook.com/MirenaandCo/ https://www.linkedin.com/company/frameless-consulting-llc/ https://www.instagram.com/mirenaandco/ Additional Resources: https://www.pilmma.org/aiworkshop https://www.pilmma.org/the-mastermind-effect https://www.pilmma.org/resources https://www.pilmma.org/mastermind
CardioNerds Cofounder Dr. Amit Goyal is joined by an esteemed group of UCLA cardiology fellows – Dr. Patrick Zakka (CardioNerds Academy Chief), Dr. Negeen Shehandeh (Chief Fellow), and Dr. Adrian Castillo – to discuss a case of primary cardiac angiosarcoma. An expert commentary is provided by Dr. Eric Yang, beloved educator, associate clinical professor of medicine, assistant fellowship program director, and founder of the Cardio-Oncology program at UCLA. Case synopsis: A female in her 40s presents to the ED for fatigue that had been ongoing for approximately 1 month. She also developed night sweats and diffuse joint pains, for which she has been taking NSAIDs. She was seen by her PCP and after bloodwork was done, was told she had iron deficiency so was on iron replacement therapy. Vital signs were within normal limits. She was in no acute distress. Her pulmonary and cardiac exams were unremarkable. Her lab studies showed a Hb of 6.6 (MCV 59) and platelet count of 686k. CXR was without significant abnormality, and EKG showed normal sinus rhythm. She was admitted to medicine and received IV iron (had not consented to receiving RBC transfusion). GI was consulted for anemia work-up. Meanwhile, she developed a new-onset atrial fibrillation with rapid ventricular response seen on telemetry, for which Cardiology was consulted. A TTE was ordered in part of her evaluation, and surprisingly noted a moderate pericardial effusion circumferential to the heart. Within the pericardial space, posterior to the heart and abutting the RA/RV was a large mass measuring approximately 5.5x5.9 cm. After further imaging work-up with CMR and PET-CT, the mass was surgically resected, and patient established care with outpatient oncology for chemotherapy. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - primary cardiac angiosarcoma Episode Schematics & Teaching Pearls – primary cardiac angiosarcoma The pericardium is composed of an outer fibrous sac, and an inner serous sac with visceral and parietal layers. Pericardial masses can be primary (benign or malignant) or metastatic. There are other miscellaneous pericardial masses. Imaging modalities for the pericardium include echocardiography, cardiac CT and cardiac MRI. There is also role for PET-CT in pericardial imaging for further characterization of pericardial masses. Cardiac angiosarcomas are extremely rare but are the most common cardiac primary malignant tumors. Evidence-based management if lacking because of paucity of clinical data given the rarity of cardiac angiosarcomas. Surgery is the mainstay of therapy. Radiotherapy and chemotherapy are often used as well. Notes – primary cardiac angiosarcoma Pericardial Anatomy The pericardium is a fibroelastic sac composed of two layers. Outer layer: fibrous pericardium (
© 2020-2025 Ivy Podcast Discovery LLC
